Amrixa Pharmaceuticals is focused on building novel mRNA-LNP therapies for poorly treated diseases.
We’re incubating at BioLabs LA @ The Lundquist Institute, and we are engaged in animal studies for our lead therapeutic, RXA-2. We completely own our IP; that includes novel mRNA sequences, manufacturing methods, and a proprietary LNP platform. We are open to exploring partnerships, licensing, and investment offers.